Bamlanivimab to Prevent Severe COVID in Inpatients

Background: We anticipate rare but important opportunities for inpatients with COVID-19 infection to receive Bamlanivimab. If inpatients are eligible and consented to receive the monoclonal infusion, this may prevent further complications and future admissions related COVID-19 infection.

Inclusion Criteria for Bamlanivimab infusion (Age ≥ 18 yrs [at UNMH] and Weigh at least 40 kg):

- Are admitted for a non-COVID related diagnosis
- Do not have an oxygen requirement above their baseline due to COVID-19
- Are within 10 days of symptom onset
- Have at least one high-risk condition posing a risk for progressing to severe COVID-19 disease

High-Risk Condition for Emergency Use Authorization (EUA) of Bamlanivimab:

- BMI ≥ 35
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease (e.g., HIV)
- Currently receiving immunosuppressive treatment
- Individuals aged 65 or older
- Age 55 and older AND have:
    - Cardiovascular disease, *or*
    - High blood pressure, *or*
    - Chronic obstructive pulmonary disease (COPD)/other chronic respiratory disease

If the adult inpatient may be eligible for bamlanivimab infusion, providers will:

- Complete the "Bamlanivimab Inpatient Screening Form" to document eligibility (accessed via "Adult COVID-19 ED & ICU" or "Adult SAC COVID-19" Powerplans in EMR).
- Provide the patient with Bamlanivimab EUA Fact Sheet (click here)
- Consent the patient for Bamlanivimab infusion
- Document consent and receipt of the EUA Fact Sheet in the "Bamlanivimab EUA Attestation"
- Order bamlanivimab 700 mg IV infusion over 60 min for a one-time dose and medications to manage possible infusion reactions ("COVID-19 Monoclonal Ab Infusion" Powerplan).

Allergic reaction may occur during or after bamlanivimab infusion. These may include:

- Fever, chills, nausea, headache, shortness of breath, hypotension, wheezing, angioedema, swelling of face or throat, rash including hives, itching, muscle aches, and dizziness

Management of adverse reactions:

- For Severe or anaphylactic infusion reactions, STOP the infusion, notify the provider, and activate Rapid Response and/or call 333
- For mild infusion reactions, STOP the infusion and notify the provider.
    - If restarting the infusion, start at 50% of the previous rate.

If a patient has adverse effects related to bamlanivimab occur, report any event using the Patient Safety Intelligence System (click here for access on UNMH Intranet).